MedPath

Turkish Acquired Haemophilia Registry

Conditions
Acquired Haemophilia
Interventions
Drug: rFVIIIa, aPCC, FVIII, DDAVP, Azathioprine, Rituximab, Cyclosporin
Registration Number
NCT01403740
Lead Sponsor
Turkish Society of Hematology
Brief Summary

Turkish Acquired Haemophilia Registry is a database in which information about clinical features and therapeutic management of acquired haemophilia is collected in Turkey.This is a multicentre, retrospective and prospective registry of subjects diagnosed and/or treated for acquired haemophilia. Patients will be registered and the response to different therapies, details of each bleeding episode and the outcome of haemostatic and immunosuppressive therapy (IST) will be recorded. Any male or female subject diagnosed with inhibitors to FVIII or other factors and treated for acquired haemophilia can be entered on the registry. Patients will be treated according to local practice. No additional tests or procedures are required by the registry. The retrospective period will not be time-limited and data will be collected from those recorded in the hospital notes. The prospective period will begin in September 1.2011, and will last for two years.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
250
Inclusion Criteria
  • Acquired haemophilia diagnosis, written consent
Exclusion Criteria
  • Being unable to give written consent

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Acquired haemophilia patientsrFVIIIa, aPCC, FVIII, DDAVP, Azathioprine, Rituximab, Cyclosporin-
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Trakya University Haematology Clinic

🇹🇷

Edirne, Turkey

© Copyright 2025. All Rights Reserved by MedPath